Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Patience Pays Off for Cytokinetics

This article was originally published in Start Up

Executive Summary

Cytokinetics' recently signed research collaboration with GlaxoSmithKline provides some third-party validation for the three-year-old start-up's cytoskeleton-based technology platform. The deal which provides Cytokinetics with at least $50 million in committed funding, centers on the discovery and development of small molecule therapeutics that target mitotic kinesins for applications in the treatment of cancer. Cytokinetics also stands to earn substantial milestones on royalties in connection with the mitotic kinesins that are the subject of the collaboration, as well as buy-in rights on any drug candidates.

Related Content


Related Companies

Related Deals




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts